


RealRate

## PHARMACEUTICAL 2021

## Trillium Therapeutics Inc. Rank 94 of 409





## PHARMACEUTICAL 2021



## Trillium Therapeutics Inc. Rank 94 of 409

The relative strengths and weaknesses of Trillium Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Trillium Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 249% points. The greatest weakness of Trillium Therapeutics Inc. is the variable Revenues, reducing the Economic Capital Ratio by 43% points.

The company's Economic Capital Ratio, given in the ranking table, is 41%, being 395% points above the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	298,529
Cost of Goods Sold	0
Intangible Assets	783
Liabilities, Current	21,418
Liabilities, Non-Current	557
Other Assets	732
Other Compr. Net Income	0
Other Expenses	102
Other Liabilities	0
Other Net Income	2,211
Property and Equipment	778
Research and Development	25,348
Revenues	148
Selling, General and Administrative Expense	36,255

Output Variable	Value in 1000 USD
Assets	300,822
Liabilities	21,975
Expenses	61,705
Stockholders Equity	278,847
Net Income	-59,346
Comprehensive Net Income	-59,346
Economic Capital Ratio	41%